Medical World

06/28/2022

Breyanzi Approved as Second-Line Treatment for Large B-Cell Lymphoma

Learn more -> https://www.empr.com/home/news/breyanzi-approved-as-second-line-treatment-for-large-b-cell-lymphoma/

06/07/2022

Roflumilast Foam Looks Promising in Seborrheic Dermatitis Trial

Learn more -> https://www.empr.com/home/news/drugs-in-the-pipeline/roflumilast-foam-looks-promising-in-seborrheic-dermatitis-trial/

05/20/2022

FDA Modifies REMS Requirements for Opioid Analgesic Dsuvia

Learn more -> https://www.empr.com/home/news/fda-modifies-rems-requirements-for-opioid-analgesic-dsuvia/

04/29/2022

Vivjoa Approved for Recurrent Vulvovaginal Candidiasis

Learn more ->

The approval was based on data from three phase 3 trials, which included female patients aged 12 years and older with at least 3 episodes of acute VVC in the past 12 months.

04/22/2022

PDE5 Inhibitors Prescribed for Men on Oral Nitrates for IHD

Learn more -> https://www.empr.com/home/news/pde5-inhibitors-prescribed-for-men-on-oral-nitrates-for-ihd/

04/14/2022

CDC Extends Mask Mandates on Planes, Trains to May 3

Learn more -> https://www.empr.com/home/news/cdc-extends-mask-mandates-on-planes-trains-to-may-3/

04/06/2022

Edsivo Gets Breakthrough Therapy Status for Vascular Ehlers-Danlos Syndrome

Learn more ->

Edsivo is intended to help patients with vEDS by promoting normal collagen synthesis in the blood vessels, and by shifting the pressure load away from the vessels most prone to dissection and rupture.

03/30/2022

Cabenuva Approval Expanded to Include Adolescent With HIV

Learn more -> https://www.empr.com/home/news/cabenuva-approval-expanded-to-include-adolescent-with-hiv/

03/25/2022

Hydrocortisone Does Not Up Survival Without BPD in Preemies

Learn more -> https://www.empr.com/home/news/hydrocortisone-does-not-up-survival-without-bpd-in-preemies/

03/23/2022

Syringe Malfunction Prompts Recall of Anaphylaxis Treatment

Learn more ->

Certain lots of Symjepi (epinephrine) Injection 0.15mg and 0.3mg prefilled single-dose syringes are being recalled.

03/18/2022

Pegcetacoplan Continues to Reduce Geographic Atrophy Lesion Growth: 18-Month Data

Learn more ->

DERBY and OAKS are phase 3, multicenter, randomized, double-masked, sham-controlled studies.

03/16/2022

Genomic Analysis Reveals Possible Role of AMH in PCOS Infertility
A genomic study has revealed new insights into the function of anti-Müllerian hormone in the context of reproductive biology and fertility.

Learn more ->

A genomic study has revealed new insights into the function of anti-Müllerian hormone in the context of reproductive biology and fertility.